AlphaCentric Advisors LLC Buys 4,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AlphaCentric Advisors LLC raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 40.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 15,500 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,500 shares during the quarter. Jazz Pharmaceuticals accounts for about 1.3% of AlphaCentric Advisors LLC’s investment portfolio, making the stock its 24th biggest position. AlphaCentric Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,727,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc boosted its position in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC increased its stake in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $33,000. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on JAZZ. Piper Sandler reduced their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Royal Bank of Canada raised their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Wells Fargo & Company cut their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.43.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $109.41 on Tuesday. The company’s 50-day moving average is $110.58 and its 200 day moving average is $109.59. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The company has a market capitalization of $6.76 billion, a P/E ratio of 18.80, a price-to-earnings-growth ratio of 1.38 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.48.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.